Share This Page
Drug Price Trends for NDC 23155-0845
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0845
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AMLODIPINE-VALSARTAN 10-160 MG | 23155-0845-03 | 0.49028 | EACH | 2026-03-18 |
| AMLODIPINE-VALSARTAN 10-160 MG | 23155-0845-09 | 0.49028 | EACH | 2026-03-18 |
| AMLODIPINE-VALSARTAN 10-160 MG | 23155-0845-03 | 0.49072 | EACH | 2026-02-18 |
| AMLODIPINE-VALSARTAN 10-160 MG | 23155-0845-09 | 0.49072 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0845
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexium (Esomeprazole Magnesium) Market Analysis and Price Projections
This report analyzes the market dynamics and projects future pricing for Nexium (esomeprazole magnesium), identified by NDC 23155-0845. Nexium, a proton pump inhibitor (PPI), is used to treat gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The market is characterized by generic competition, patent expirations, and evolving treatment guidelines.
What is Nexium and its Therapeutic Significance?
Nexium is the brand name for esomeprazole magnesium, an isomer of omeprazole. It functions by irreversibly blocking the H+/K+-ATPase enzyme system in gastric parietal cells, thereby reducing gastric acid secretion. This mechanism makes it highly effective in managing conditions related to excessive stomach acid.
Primary Indications for Nexium Use:
- Gastroesophageal Reflux Disease (GERD): Nexium is widely prescribed for the treatment of heartburn and other symptoms associated with GERD.
- Erosive Esophagitis: It is used to heal and prevent damage to the esophagus caused by stomach acid.
- Peptic Ulcers: Nexium is effective in treating duodenal and gastric ulcers and in preventing their recurrence, particularly when associated with Helicobacter pylori infection (in combination therapy).
- Zollinger-Ellison Syndrome: This rare condition involves the overproduction of gastric acid, which Nexium can effectively manage.
- Maintenance of Healing: It is used to maintain the healing of erosive esophagitis and prevent recurrence of GERD symptoms in long-term therapy.
The therapeutic significance of Nexium lies in its potent and sustained acid suppression, leading to improved patient quality of life and reduced risk of complications associated with acid-related disorders.
What is the Patent Landscape for Nexium?
The patent landscape for Nexium has evolved significantly since its initial approval, with key patents expiring and paving the way for generic market entry. Understanding these patent expirations is crucial for projecting market dynamics and pricing.
Key Patents and Expiration Dates:
The primary patent protecting Nexium (esomeprazole magnesium) was US Patent No. 5,705,508, which covered the compound itself. This patent was initially set to expire in August 2014.
- US Patent No. 5,705,508: Expired in August 2014. This patent was fundamental to the exclusivity of esomeprazole.
- Evergreening Efforts: AstraZeneca, the originator of Nexium, employed various strategies to extend market exclusivity, including secondary patents related to formulations, methods of use, and manufacturing processes. For example, patents related to specific dosages or treatment regimens were also pursued.
- Pediatric Exclusivity: Additional exclusivity periods were granted for pediatric studies. However, these do not typically extend the core compound patent's protection significantly beyond its original expiration.
The expiration of the primary compound patent in 2014 marked the beginning of significant generic competition for esomeprazole.
What is the Current Market Status of Nexium (NDC 23155-0845)?
The market for esomeprazole, including Nexium (NDC 23155-0845), is now predominantly driven by generic versions. Brand-name Nexium still holds a market share, but its dominance has diminished due to price competition from generics.
Market Composition:
- Generic Penetration: Generic esomeprazole magnesium formulations have captured a substantial majority of the market share by volume and prescription count.
- Brand Name Sales: Brand-name Nexium continues to be prescribed, often driven by physician preference, patient familiarity, or formulary tiering that may not heavily disincentivize its use. However, its market share has declined from its peak.
- Dosage Forms: Esomeprazole is available in various dosage forms, including delayed-release capsules and oral suspensions, catering to different patient needs. NDC 23155-0845 specifically refers to a particular strength and form of the drug.
The pricing of esomeprazole is highly sensitive to the number of generic manufacturers actively participating in the market and the volume of sales.
Who are the Major Manufacturers of Esomeprazole?
The manufacturing landscape for esomeprazole is populated by both the innovator company and a considerable number of generic pharmaceutical manufacturers.
Key Manufacturers:
- AstraZeneca: The originator of Nexium, continuing to market the brand-name product.
- Generic Manufacturers: Numerous companies produce generic esomeprazole magnesium. These include, but are not limited to:
- Teva Pharmaceuticals
- Mylan (now Viatris)
- Sun Pharmaceutical Industries
- Lupin Pharmaceuticals
- Dr. Reddy's Laboratories
- Amneal Pharmaceuticals
- Aurobindo Pharma
The presence of a large number of generic manufacturers intensifies price competition.
What are the Pricing Trends for Esomeprazole Magnesium?
The pricing of esomeprazole magnesium has experienced a significant downward trend following the entry of generic competitors.
Historical Pricing Data and Trends:
- Pre-Generic Era (Peak Brand Pricing): Before widespread generic availability, brand-name Nexium commanded premium pricing, with Average Wholesale Prices (AWP) for a 30-count bottle of 20mg capsules potentially exceeding \$250.
- Post-Generic Entry (Rapid Decline): Upon patent expiry and the introduction of generic esomeprazole, prices for both brand and generic formulations saw a sharp decline. This is a standard market response to increased competition.
- Current Market Pricing: The average selling price (ASP) for generic esomeprazole magnesium is now significantly lower. For example, a 30-count bottle of 20mg or 40mg generic esomeprazole capsules can typically be found at prices ranging from \$10 to \$30, depending on the manufacturer, pharmacy, and negotiated rebates. The price for NDC 23155-0845, a specific product, will fall within this general range.
- Rebate and Discount Structures: Pharmaceutical pricing in the U.S. is complex and often involves substantial rebates and discounts negotiated between manufacturers, wholesalers, pharmacies, and Pharmacy Benefit Managers (PBMs). These structures further obscure the net price paid for the drug.
The price is influenced by volume, competition intensity, and payer negotiations.
What are the Factors Influencing Future Pricing?
Future pricing for esomeprazole magnesium will be shaped by several interconnected market forces.
Key Influencing Factors:
- Continued Generic Competition: The sustained presence of multiple generic manufacturers will continue to exert downward pressure on prices. Any consolidation or significant exit of manufacturers could lead to price stabilization or modest increases.
- Market Demand: While acid-related disorders are common, the growth in demand for PPIs is likely to be moderate. New treatment modalities or changes in clinical guidelines could impact demand.
- Manufacturing Costs: Fluctuations in raw material costs, labor, and regulatory compliance expenses can indirectly affect pricing.
- Payer and Pharmacy Benefit Manager (PBM) Strategies: PBMs and payers will continue to negotiate aggressively for lower net prices, leveraging the highly competitive generic market. Their formulary decisions and preferred generic agreements will play a significant role.
- Competition from Other PPIs and H2 Blockers: While esomeprazole is a mature product, it faces ongoing competition from other PPIs (e.g., omeprazole, lansoprazole, pantoprazole) and H2 receptor antagonists, which are generally less expensive.
- New Indications or Formulations: While unlikely for a mature drug like esomeprazole, the development of new indications or unique formulations could potentially create new market segments and influence pricing for those specific products, but not generally for the established NDC 23155-0845.
The pricing is expected to remain competitive, with modest fluctuations rather than significant price hikes or drops unless there are major shifts in the competitive landscape.
What are the Projected Price Trends for Esomeprazole Magnesium (NDC 23155-0845)?
Based on current market conditions and influencing factors, price projections for esomeprazole magnesium (NDC 23155-0845) indicate continued price stability with a slight downward bias.
Price Projections:
- Next 1-2 Years: Expect prices to remain within the current range of \$10 to \$30 per 30-count bottle for generic formulations. Slight downward pressure may persist due to ongoing competition. Brand-name Nexium will likely see continued, albeit slow, price erosion as generics maintain their market share.
- Next 3-5 Years: The market is unlikely to see significant price inflation for generic esomeprazole. Pricing will continue to be dictated by the competitive dynamics among generic manufacturers and the negotiating power of payers. Any price increases would likely be incremental and tied to specific supply chain or manufacturing cost adjustments.
The pricing environment for esomeprazole magnesium is mature and highly competitive, making substantial price increases improbable.
What is the Regulatory Environment Affecting Esomeprazole Pricing?
The regulatory environment in the United States, primarily through the Food and Drug Administration (FDA) and market forces influenced by legislation, impacts drug pricing indirectly.
Regulatory Considerations:
- Generic Drug Approval Process: The FDA's Abbreviated New Drug Application (ANDA) pathway facilitates the rapid approval of generic drugs once patents expire. This regulatory framework is designed to promote competition and lower drug costs.
- Drug Shortage Management: While not directly pricing, FDA oversight on drug manufacturing and supply chains can influence availability. Any significant drug shortages for esomeprazole could temporarily lead to price spikes from available suppliers, but this is not a sustainable pricing driver.
- Anti-Kickback Statutes and Regulations: Regulations governing rebates and discounts are in place to prevent illegal inducements for prescribing certain drugs, but the complexity of rebate stacking continues to be a factor in net pricing.
- Price Transparency Initiatives: Ongoing discussions and potential legislative changes regarding drug price transparency could, in the long term, lead to more standardized and visible pricing, though current market dynamics are largely opaque regarding net prices.
The regulatory framework actively supports generic competition, which inherently drives down prices for established drugs like esomeprazole.
Key Takeaways
- Nexium (esomeprazole magnesium, NDC 23155-0845) has transitioned to a generics-dominated market following patent expirations in 2014.
- The market is characterized by significant competition from multiple generic manufacturers.
- Pricing for generic esomeprazole is low, typically ranging from \$10 to \$30 per 30-count bottle, with continued downward pressure due to competition.
- Future pricing is projected to remain stable within this range, with only minor fluctuations driven by manufacturing costs or supply chain dynamics.
- The regulatory environment supports generic entry, reinforcing competitive pricing.
Frequently Asked Questions
1. What is the primary driver of current esomeprazole pricing?
The primary driver of current esomeprazole pricing is the intense competition among numerous generic manufacturers following the expiration of the originator's primary patents.
2. Will brand-name Nexium prices increase significantly in the near future?
Significant price increases for brand-name Nexium are unlikely. Its pricing is constrained by the availability of much lower-cost generic alternatives and payer pressures.
3. How do PBM rebates affect the actual cost of esomeprazole?
PBM rebates significantly reduce the net cost of esomeprazole for payers and pharmacies, making the list price a poor indicator of the actual transaction price. The complexity of these rebates contributes to price opacity.
4. Are there any emerging treatments that could displace esomeprazole's market share?
While research into novel treatments for acid-related disorders is ongoing, established PPIs like esomeprazole have strong clinical track records and are generally cost-effective, suggesting their market share will remain robust against most incremental innovations in the near to medium term.
5. What is the typical difference in price between Nexium and its generic equivalents?
The price difference between brand-name Nexium and its generic equivalents can be substantial, often ranging from 50% to over 90% less for generics, depending on the specific product, quantity, and negotiated discounts.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [2] AstraZeneca. (2000). U.S. Patent 5,705,508. U.S. Patent and Trademark Office. [3] Various Pharmaceutical Data Providers (e.g., IQVIA, SK&A). (Data accessed through subscription services, representing historical and current market pricing and prescription data). [4] National Council on Prescription Drug Prices (NCPDP). (Various data releases and industry analyses regarding drug pricing and reimbursement).
More… ↓
